About us

"AlphaMol accelerates GPCR drug discovery in an ultimately efficient way"

AlphaMol attracts leading scientists in the areas of both biological computing and pharmaceutical sciences to join the team. We develop cutting-edge bio-technologies to substantially speed up modern drug discovery. We aim at challenging essential diseases in human health.

AlphaMol has sites in Basel in Switzerland as well as in Shanghai and Shenzhen in China. 

AlphaMol has four major departments in research including: computational drug discovery, medicinal chemistry, cell biology & biochemistry as well as pharmacology. 

Co-founders

Dr. Shuguang Yuan

Co-founder

Dr Shuguang Yuan finished his doctoral dissertation with the supports of Maria Curia Fellowship. It was conducted in three different institutes in Europe, including Swiss Federal Institute of Technology Lausanne (EPFL, Switzerland), Polish Academy of Science (Poland) and KULeuven University (Belgium).  He has been in the list of "Global Top 2% Scientists" since 2022.

His research is mainly focusing on G protein-coupled receptors (GPCRs) molecular mechanism as well as drug discovery via computational biology and artificial intelligence.

In June 2013, he was awarded with a PhD title with the honor of distinguished thesis. Following that, he was offered the Marie Curie ETH Postdoc Fellowship. In 2014, Dr. Yuan proposed a theory about the activation mechanism and the continuous water channel of GPCRs, which could be used to guide the design of   agonist/antagonist molecules. 

Furthermore, Dr. Yuan worked in big pharma in Basel in Switzerland for several years. He has advanced several of his designed molecules into clinical trials sucessfully. 
Dr. Horst Vogel

Co-founder

Dr. Horst Vogel is a member of Swiss Academy of Science as well as that of National Academy of Inventors, USA. He is also an emeritus professor at EPFL. He has also been in the list of "Global Top 2% Scientists" for a long time.

The research of Dr. Vogel is mainly focus on membrane protein structural and sensor biotechnology development, especially that of GPCRs. He has applied several of his scientific findings to measure important parameters of drug molecular against membrane proteins which were totally missing or difficult to obtain by traditional methods.

Dr. Vogel studied Chemistry at the University of Würzburg/Germany. After his diploma thesis in Physical Chemistry. He went to the Max-Planck-Institute for Biophysical Chemistry in Göttingen where he performed his PhD under the supervision of Prof. M. Eigen and Prof. A. Weller. After that, he worked at different institutes including: the Max-Planck-Institute for Biology in Tübingen, Biocenter of the University of Basel as well as the Karolinska Institute in Stockholm respectively. In 1994 he was appointed as a professor of Physical Chemistry at the EPFL, where he worked for more than 25 years.